Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement

医学 布比卡因 麻醉 可视模拟标度 不利影响 随机对照试验 局部麻醉剂 骨关节炎 外科 患者满意度 内科学 病理 替代医学
作者
Thomas W. Hamilton,Ruth Knight,Jamie R. Stokes,Ines Rombach,Cushla Cooper,Loretta Davies,Susan Dutton,Karen Barker,Jonathan Cook,Sarah E Lamb,David W. Murray,Lisa Poulton,Ariel Wang,Louise Strickland,Bernard van Duren,José Leal,David Beard,Hemant Pandit,Kirti Mohalkar,Simon Jones
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:157 (6): 481-481 被引量:22
标识
DOI:10.1001/jamasurg.2022.0713
摘要

Importance

More than half of patients who undergo knee replacement surgery report substantial acute postoperative pain.

Objective

To evaluate the efficacy and cost-effectiveness of periarticular liposomal bupivacaine for recovery and pain management after knee replacement.

Design, Setting, and Participants

This multicenter, patient-blinded, pragmatic, randomized clinical superiority trial involved 533 participants at 11 institutions within the National Health Service in England. Adults undergoing primary unilateral knee replacement for symptomatic end-stage osteoarthritis were enrolled between March 29, 2018, and February 29, 2020, and followed up for 1 year after surgery. Follow-up was completed March 1, 2021. A per-protocol analysis for each coprimary outcome was performed in addition to the main intention-to-treat analysis.

Interventions

Two hundred sixty-six milligrams of liposomal bupivacaine admixed with 100 mg of bupivacaine hydrochloride compared with 100 mg of bupivacaine hydrochloride alone (control) administered by periarticular injection at the time of surgery.

Main Outcome and Measures

The coprimary outcomes were Quality of Recovery 40 (QoR-40) score at 72 hours and pain visual analog scale (VAS) score area under the curve (AUC) from 6 to 72 hours. Secondary outcomes included QoR-40 and mean pain VAS at days 0 (evening of surgery), 1, 2, and 3; cumulative opioid consumption for 72 hours; functional outcomes and quality of life at 6 weeks, 6 months, and 1 year; and cost-effectiveness for 1 year. Adverse events and serious adverse events up to 12 months after randomization were also assessed.

Results

Among the 533 participants included in the analysis, the mean (SD) age was 69.0 (9.7) years; 287 patients were women (53.8%) and 246 were men (46.2%). Baseline characteristics were balanced between study groups. There was no difference between the liposomal bupivacaine and control groups in QoR-40 score at 72 hours (adjusted mean difference, 0.54 [97.5% CI, −2.05 to 3.13];P = .64) or the pain VAS score AUC at 6 to 72 hours (−21.5 [97.5% CI, −46.8 to 3.8];P = .06). Analyses of pain VAS and QoR-40 scores demonstrated only 1 statistically significant difference, with the liposomal bupivacaine arm having lower pain scores the evening of surgery (adjusted difference −0.54 [97.5% CI, −1.07 to −0.02];P = .02). No difference in cumulative opioid consumption and functional outcomes was detected. Liposomal bupivacaine was not cost-effective compared with the control treatment. No difference in adverse or serious adverse events was found between the liposomal bupivacaine and control groups.

Conclusions and Relevance

This study found no difference in postoperative recovery or pain associated with the use of periarticular liposomal bupivacaine compared with bupivacaine hydrochloride alone in patients who underwent knee replacement surgery.

Trial Registration

isrctn.com Identifier:ISRCTN54191675
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Culto完成签到,获得积分10
刚刚
1秒前
JIE完成签到,获得积分10
1秒前
houjibofa发布了新的文献求助10
2秒前
田様应助幽默平安采纳,获得10
5秒前
可爱的函函应助刘小小123采纳,获得10
6秒前
瓣落的碎梦完成签到,获得积分0
8秒前
善学以致用应助momo采纳,获得10
9秒前
孝顺的觅风完成签到 ,获得积分10
9秒前
11秒前
刘小小123发布了新的文献求助10
14秒前
健壮的面包完成签到,获得积分10
14秒前
17秒前
孙燕应助科研界的恩希玛采纳,获得20
20秒前
21秒前
迷茫的一代完成签到,获得积分10
23秒前
量子星尘发布了新的文献求助10
23秒前
xingxingwang完成签到,获得积分10
24秒前
春来发布了新的文献求助30
25秒前
26秒前
26秒前
刘小小123完成签到,获得积分20
26秒前
xzy完成签到 ,获得积分10
27秒前
搜集达人应助无情向梦采纳,获得10
29秒前
阿伟1999发布了新的文献求助50
31秒前
momo发布了新的文献求助10
32秒前
li完成签到,获得积分10
33秒前
如此发布了新的文献求助10
35秒前
36秒前
赵静1234567890完成签到,获得积分10
36秒前
xxxllllll发布了新的文献求助10
40秒前
科研通AI2S应助科研通管家采纳,获得10
40秒前
Owen应助科研通管家采纳,获得10
40秒前
乐乐应助科研通管家采纳,获得10
40秒前
科研通AI5应助科研通管家采纳,获得10
40秒前
YamDaamCaa应助科研通管家采纳,获得50
40秒前
科研通AI5应助科研通管家采纳,获得10
40秒前
科目三应助科研通管家采纳,获得10
41秒前
爆米花应助科研通管家采纳,获得10
41秒前
稳重淇完成签到 ,获得积分10
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173